Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Frontiers in Nutrition|August 23, 2021
A Root in Synapsis and the Other One in the Gut Microbiome-Brain Axis: Are the Two Poles of Ketogenic Diet Enough to Challenge Glioblastoma?Liliana Montella, Federica Sarno, Lucia Altucci, et al.
Oncotarget|June 18, 2020
Second line trastuzumab emtansine following horizontal dual blockade in a real-life settingSalvatore Del Prete, Liliana Montella, Grazia Arpino, et al.
Cancers|June 2, 2021
Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer CellsMaria Maddalena Laterza, Vincenza Ciaramella, Bianca Arianna Facchini, et al.
Frontiers in Immunology|September 5, 2022
Immunological signature of patients with thymic epithelial tumors and Good syndromeAnna Maria Malfitano, Vittoria D'Esposito, Pietro De Placido, et al.
International Journal of Cancer|December 8, 2022
Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevanceLiliana Montella, Mariella Cuomo, Nunzio Del Gaudio, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2009
Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case seriesLiliana Montella, Raffaele Addeo, Giovannella Palmieri, et al.
Future Oncology (London, England)|December 5, 2014
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trialGiovannella Palmieri, Carlo Buonerba, Margaret Ottaviano, et al.
Diagnostics (Basel, Switzerland)|June 12, 2026
When Lymph Nodes Don't Lie: Report of Three Unusual Presentations of Thoracic TumorsStefano Lucà, Francesco Barbato, Amedeo Di Maio, et al.
Critical Reviews in Oncology/Hematology|June 1, 2020
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysisCarlo Buonerba, Matteo Ferro, Pasquale Dolce, et al.
Frontiers in Oncology|May 21, 2025
Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitorsMarianna Caterino, Giorgio Lo Giudice, Vincenzo Damiano, et al.
Pageof 7